Exilby Receives Marketing Authorization in Germany and FDA Breakthrough Therapy Designation
Vertanical, a Munich‑based pharmaceutical company, announced that its investigational drug Exilby (also known as VER‑01) has been granted marketing authorization in Germany for the treatment of chronic low back pain with a neuropathic component. The authorization follows a positive evaluation by German health authorities and comes shortly after the United States Food & Drug Administration awarded Exilby a Breakthrough Therapy Designation, a status intended to speed up development and review of medicines that show substantial improvement over existing therapies.
Exilby is positioned as the first non‑opiate, full‑spectrum cannabis‑derived medication to receive such regulatory recognition worldwide. The product is a standardized extract from a proprietary cannabis strain, formulated to deliver a consistent mixture of cannabinoids, terpenes and other bioactive compounds that the company says were selected for their potential role in pain modulation.
Clinical Development and Trial Results
According to Vertanical, the German authorization and the FDA’s Breakthrough Therapy designation are based on data from two randomized, controlled Phase 3 trials that enrolled more than 1,200 patients suffering from chronic low back pain. The studies reported:
- Statistically significant reductions in pain scores compared with placebo.
- A favorable tolerability profile, with no evidence of physical dependence or withdrawal signals observed during the treatment period.
- In a head‑to‑head Phase 3 study that directly compared Exilby to opioid analgesics, the cannabis‑based extract demonstrated superior pain reduction and better gastrointestinal tolerability than the opioid comparator.
These outcomes echo the regulatory pathway that led to the approval of Epidiolex in 2018, the first purified cannabidiol (CBD) medication for certain seizure disorders. Unlike Epidiolex, which contains a single active compound, Exilby is a full‑spectrum preparation that retains over 100 phytochemicals, including THC, CBD and cannabigerol (CBG).
Comparison with Existing Treatments
Chronic low back pain affects an estimated one billion people worldwide, with roughly ten million cases in Germany and sixty million in the United States. For many patients, long‑term opioid therapy remains the standard of care, despite concerns about addiction, overdose and gastrointestinal side effects. The trial data suggest that Exilby may offer an effective analgesic alternative without the dependence liability associated with opioids.
By demonstrating both efficacy and a tolerability advantage over opioids in a direct comparison, Exilby addresses a significant unmet need in pain management and could shift prescribing patterns toward non‑opiate botanical therapies.
Regulatory Pathway in Europe and the United States
Vertanical plans to launch Exilby in Germany and Austria in September 2025. Because the European Union operates a mutual recognition procedure for centrally authorized medicines, the company anticipates that approval for the broader EU market could follow within weeks of the German decision. A submission to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) is scheduled for later this year, with a view to securing UK marketing authorization before the end of 2025.
The path to FDA approval in the United States remains longer. Vertanical has initiated a Phase 3 trial involving U.S. patients to confirm safety and efficacy for the same indication. The company expects to have trial results available for analysis in 2027; if the data are supportive, a New Drug Application (NDA) would be submitted to the FDA in 2028. The agency’s prior approval of Epidiolex and the recent rescheduling of certain FDA‑approved cannabis‑derived products provide a precedent, but the multi‑component nature of Exilby adds complexity to the safety assessment, as each constituent must be evaluated for potential interactions and risks under current FDA guidance.
Industry Impact and Future Outlook
Legal and pharmaceutical analysts view the German authorization as a milestone for the medical cannabis sector. It underscores how rigorous clinical development can reshape the perception of cannabis‑based products from Schedule I substances to legitimate therapeutic options. The Controlled Substances Act’s original classification of cannabis as having no accepted medical use is increasingly at odds with accumulating evidence from well‑controlled trials like those supporting Exilby.
Should Exilby achieve commercial success in Europe and eventually gain U.S. approval, it could capture a sizable share of the global chronic pain market, potentially surpassing the annual sales figures seen with Epidiolex. The product’s full‑spectrum profile also invites further research into the entourage effect—the hypothesis that the combined action of multiple cannabis compounds may enhance therapeutic outcomes.
Stakeholders, including physicians, patients and policymakers, will continue to monitor the drug’s real‑world performance, safety profile and impact on opioid prescribing trends. Transparent post‑marketing surveillance and independent research will be essential to confirm the early signals observed in the clinical trials.
For additional details on the announcement and regulatory context, see the original press release: Here
